Immune checkpoint inhibitors such as pembrolizumab are increasingly used in cancer therapy, yet immune-related adverse events like immune-mediated liver injury from checkpoint inhibitors remain challenging to diagnose and manage. Most cases arise early in treatment and respond to corticosteroids, but rare delayed or refractory presentations have been described. We report a unique case of delayed-onset, steroid-refractory immune-mediated liver injury from checkpoint inhibitors requiring escalation of therapy despite prolonged discontinuation of the causative agent, highlighting the need for continued vigilance and individualized management strategies in patients receiving immune checkpoint inhibitors.
Keywords: cancer; drug-induced liver injury; hepatitis.; immune checkpoint inhibitors; immune-related adverse events; immunotherapy.
Written work prepared by employees of the Federal Government as part of their official duties is, under the U.S. Copyright Act, a “work of the United States Government” for which copyright protection under Title 17 of the United States Code is not available. As such, copyright does not extend to the contributions of employees of the Federal Government.